Targeting BCL-2 regulated apoptosis in cancer

The ability of a cell to undergo mitochondrial Apoptosis is governed by pro- and anti-apoptotic members of the Bcl-2 protein family. The equilibrium of pro- versus anti-apoptotic Bcl-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the Bcl-2 Family can act as a barrier to Apoptosis and facilitate tumour development and resistance to Cancer therapy. Here we discuss the Bcl-2 Family, their deregulation in Cancer and recent pharmaceutical developments to target specific members of this family as Cancer therapy.